Additional Relevant Details Key Results from AROHIF21001
17 patients have been enrolled to receive intravenous injections of 225 mg weekly (cohort 1, n=7) or 525 mg weekly (cohort 2, n=10)The study has progressed to a dose of 1050 mg weekly (cohort 3), which is currently enrolling patientsHIF2α protein H-score was assessed via immunohistochemistry9 of 17 patients had tumor samples that could be evaluated7 of 9 demonstrated reductions in HIF2αReductions ranged from -9% to -82% with a mean reduction of -48%Efficacy was assessed by Response Evaluation Criteria in Solid Tumors (RECIST)In cohort 2, one subject had a partial response with approximately 65% tumor shrinkage and 5 had a best response of stable disease4 subjects in cohort 2 remain on drug with stable disease with treatment durations between 12 and 24 weeksTo date, investigational ARO-HIF2 has been generally well tolerated at doses of up to 525 mg weeklyNo cases of anemia related to drug have been reported